Literature DB >> 6194771

The WHO programme for prevention and control of viral, chlamydial, and rickettsial diseases. Brief review.

F A Assaad, G C Schild.   

Abstract

Through the advancement of biological and medical sciences and the application of modern technology, the disease burden imposed by viral, chlamydial and rickettsial disease has steadily decreased. Smallpox has been eradicated, poliomyelitis is under control in many countries, and measles, mumps and rubella viruses may eventually be eliminated in many developed countries. New and improved vaccines have also recently become available for rabies and hepatitis. These are major advancements. Not to be overshadowed however, are the developments which may lead to the prevention or control of other infectious diseases. For many agents, recently acquired knowledge relating to virology, replication, structural and genetic characteristics, and host responses to infection pave the way for disease intervention in numerous ways. For other agents, recent advances in molecular biology make possible new classes of effective vaccines. It is crucial that these advances be incorporated as soon as possible into effective public health programmes for developing as well as developed nations. Much work yet remains, particularly in the prevention and control of respiratory diseases, diarrhoeal diseases, vector-borne diseases and hepatitis. The WHO Viral Diseases Programme has a major role in supporting laboratory and field research on new technologies and intervention strategies, in disseminating technological advances through teaching and training, and in translating the newer knowledge into action programmes for the prevention and control of viral, chlamydial and rickettsial diseases.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6194771      PMCID: PMC7086869          DOI: 10.1007/bf01311195

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  9 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Enzyme immunoassays for viral diseases.

Authors:  D E Bidwell; A Bartlett; A Voller
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

3.  Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.

Authors:  J D Frame; J M Baldwin; D J Gocke; J M Troup
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

4.  A monoclonal antibody for large-scale purification of human leukocyte interferon.

Authors:  D S Secher; D C Burke
Journal:  Nature       Date:  1980-06-12       Impact factor: 49.962

5.  Comparison of immunofluorescence and radioimmunoassay for detecting IgM antibody in infants with the congenital rubella syndrome.

Authors:  J E Cradock-Watson; M K Ridehalgh; J R Pattison; M J Anderson; H O Kangro
Journal:  J Hyg (Lond)       Date:  1979-12

6.  The Wellcome Foundation Lecture, 1980: monoclonal antibodies from hybrid myelomas.

Authors:  C Milstein
Journal:  Proc R Soc Lond B Biol Sci       Date:  1981-03-27

7.  The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizzotic and virological studies.

Authors:  J M Meegan
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

Review 8.  Advances in viral hepatitis. Report of the WHO Expert Committee on Viral Hepatitis.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1977

9.  Isolation of rhinoviruses and coronaviruses from 38 colds in adults.

Authors:  H E Larson; S E Reed; D A Tyrrell
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.